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Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is
biocompatible, chemically stable, and accessible for radiolabeling with 201Tl. We explored whether this nanoparticle enhanced
the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian
blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201Tl isotope were characterized with atomic force
microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT
and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm3) were calculated from the
SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP
accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity
in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform
for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic
applications.
1. Introduction
Two or more imaging techniques applied simultaneously
or within a very close timeframe ideally complement each
others. Powerful new high-resolution imaging tools such as
optical whole body imaging, micro-X-ray-based computed
tomography (CT), and magnetic resonance imaging (MRI)
could thus nowadays enable very good anatomical detail
fusion to functional image data of living organisms and
disease.These functional data have been obtained for decades
in nuclear medicine using positron emission tomography
(PET) and single photon emission computed tomography
(SPECT). PET and SPECT possess unparalleled sensitivity
and functionality but their resolution can be enhanced much
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further by hybrid imaging. This provides the ability of
acquiring (almost) simultaneous in vivo images of highly
resolved anatomy and accurately measured physiology in
a noninvasive manner in animal models, clinical research,
or diagnostics. This approach enables the explicit localiza-
tion as well as the quantification of metabolic activity in
target tissues [1, 2]. Nanoparticles embody unique imaging
possibilities. A high signal concentration for well-amplified
biologic readouts can be combined by their use for both
anatomy and (patho)physiology. With the availability of
novel multimodal imaging devices, the demand for inno-
vative multimodal contrast materials is higher than ever
before [1, 3]. The greatest concern of in vivo functional
imaging with isotopes is whether the isotope’s binding to
the nanoparticle is stable enough in the living organism.
Magnetic resonance imaging (MRI) is an ideal modality
to elucidate morphological qualities in living organisms. In
the past two decades, research of MRI contrast agents such
as nanoparticles (NP) with paramagnetic properties started
to burgeon. These particles were mostly paramagnetic iron
oxides such as magnetite (Fe
3
O
4
), maghemite (𝛾Fe
2
O
3
),
and other ferrites. The contrast property of these materials
(hypointense signal in T2-weighted images) is not optimal for
anatomical mapping [4, 5], where, in turn, an enhancement
(positive) in MRI signal is expected from contrast materials.
To overcome these difficulties, the development of a properT1
enhancing iron-containing particulate contrast agent seemed
to be a good solution.
Our aim was to create a biocompatible Prussian blue
nanoparticle (PBNP) (iron(II);iron(III);octadecacyanide)
platform for preclinical imaging which has three important
qualities: first, the long-term stability of the NP platform
(surface characteristics, i.e., coating to avoid phagocytosis
and aggregation, the stability of the NP component’s
diameter, and homogeneity and colloidal stability); second,
T1 signal enhancement suitable for MR imaging; and third,
the stability of the bond between the radionuclide and
nanoparticle structure in most environments.
Thanks to the special structure of PBNP (Figure 1), it is
capable of very stably binding thallium cations and thereby
acts as an appropriate SPECT radiotracer [6, 7].
The exact binding mechanism has not been published
until this time. In general chemical ion-exchange, physical
adsorption (Prussian blue crystals are dubbed “chemical
sponges” to absorbmetal ions [4, 8]), and ion trappingmay all
be involved in the PBNP-thalliumbinding process depending
on the pH condition and physical properties of particles
(e.g., particle size or moisture content) [6]. The stability of
the PBNP-thallium binding is high as quantified by Gupta
which makes Prussian blue a suitable antidote for thallium
poisoning [9].
The investigation of in vivo stability and biodistribution
of the radiolabeled PBNPs was our goal as well. Quantitative
tomographic imaging using emitted gamma rays was carried
out in a dedicated small animal SPECT/CT instrument.
Briefly, we wished to explore 201Tl radiolabeled PBNPs as a
form of chemically stable contrast material with applications
in MRI and SPECT.This approach has been patented in 2012
by two of the authors [10].
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Figure 1: The structure of Prussian blue. Citrate bound to Fe(III)
forms the coating. The colors represent the following ions or atoms,
respectively: red: C; green: N; black: Fe (both of Fe(II) and Fe(III));
blue: O; gray: 201Tl.
2. Materials and Methods
2.1. Synthesis of PBNPs. A modified method of Shok-
ouhimehr was used to prepare citrate-coated PBNPs [4].
Briefly, PBNPs were prepared by slowly adding 20mL of a
1.0mMFe(III) chloride (anhydrous) (FeCl
3
) (Sigma-Aldrich)
solution containing 0.5mmol of citric acid (Sigma-Aldrich)
to a solution containing an equimolar amount of potassium
ferrocyanide (anhydrous) (K
4
[Fe(CN)
6
]) (Sigma-Aldrich)
under rigorous stirring at 40∘C. Three samples (𝑛 = 3) were
synthesized. The products were isolated by centrifugation at
29000 rpm (Beckman Ti 50.2 rotor, 30min at 4∘C) and then
dialyzed for 3× 1 hour (14 kDa filter) (Sigma-Aldrich, D9277).
2.2. In Vitro Measurements
2.2.1. Atomic Force Microscopy. After 15min incubation the
mica surface was dried in N
2
stream. AFM images were col-
lected in noncontact mode with a Cypher S instrument (Asy-
lum Research, Santa Barbara, CA) at 1Hz line-scanning rate
in air, using a silicon cantilever (OMCLAC-160TS, Olympus,
Japan) oscillated at its resonance frequency (300–320Hz).
Temperature during the measurements was 29 ± 1∘C. AFM
amplitude-contrast images are shown in this paper. AFM
images were analyzed by using the built-in algorithms of
the AFM driver software (IgorPro, WaveMetrics Inc., Lake
Oswego, OR). Particle statistics was done by analyzing a 10
× 10 𝜇m height-contrast image with 𝑛 = 1162 particles.
Maximum height values were taken as height of particles;
rectangularity was calculated as the ratio of the particle area
to the area of a nonrotated inscribing rectangle. The closer a
particle is to a rectangle the closer this value is to unity.
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2.2.2. Transmission Electron Microscopy (TEM). Morpho-
logical investigations of the NPs were carried out on a
MORGAGNI 268(D) (FEI, Eindhoven, Netherlands) trans-
mission electron microscope. Diluted sample was dropped
and dried on a carbon-coated copper grid. Size distribution
was determined by manually measuring the diameter of 700
particles on the images, using a software custom designed for
this purpose (tem circlefind by Andra´s Wacha, MTA TTK,
Hungary).
2.2.3. Zeta Potential and Light Scattering Measurement. Zeta
potential and hydrodynamic diameter measurements were
performed using a Zetasizer Nano ZS instrument (from
Malvern Instruments Ltd., Worcestershire, UK), fitted with a
He-Ne laser (𝜆 = 633 nm) and a backscatter detector fixed at
173∘. For zeta potential measurements, PBNP samples were
diluted thirtyfold with a solution containing 0.9% NaCl in
order to mimic physiological ion concentrations. The pH of
the sample was adjusted by the addition of a 0.01M NaOH
solution. DLS measurement was performed in a W130i DLS
instrument (Avid Nano Ltd., High Wycombe, UK) using
low volume disposable cuvettes (UVette, Eppendorf Austria
GmbH).The sample was diluted tenfold with ultrapure water
and filtered through a 0.22 um membrane filter. Data were
processed with iSize 2.0 software utilizing the CONTIN
algorithm. DLS measurements were performed weekly for a
period of 6 weeks to determine colloidal stability. Samples
were stored at 4∘C.
2.2.4. Magnetic Resonance Imaging (MRI). MRI measure-
ments were performed in vitro with a nanoScan PET/MR
system (Mediso, Hungary) in a permanent magnetic field
of 1 T in a 450mT/m gradient system using a volume
transmit/receive coil with a diameter of 60mm. A phantom
consisting of six 1.5ml microcentrifuge tubes was prepared,
with each microcentrifuge tube containing a 150 𝜇l aliquot
of a PBNP solution. PBNP concentrations were 0.00mM,
0.125mM, 0.25mM, 0.38mM, 0.76mM, and 1.25mM. Parti-
cle concentrations were based on themolecular weight calcu-
lated using the illustrated crystal structure model (Figure 1).
Four different sequences were used for imaging, two of them
for relaxivity measurements and two others for basic imaging
to exploit different contrast mechanisms. T1-weighted 2D
Spin Echo sequence was acquired using the below parame-
ters: field of view (FOV) 74mm, 0.41mm in-plane resolution,
1.6mm slice thickness, and TR/TE 500/9.2ms. Fast spin
T2-weighted echo sequence was acquired with the same
geometric parameters but with TR/TE 4000/77.1ms and 4
averages. T1 relaxation rates and r1 relaxivity were calculated
from inversion prepared snapshot gradient echo (IR GRE-
SNAP) images acquired with 50mmFOV, plane resolution of
0.39mm, slice thickness of 2mm, 8 averages, TR/snap TR/TE
12000/8.2/3ms, flip angle of 8∘, and 8 different transmission
intervals ranging from 50 to 6400ms. T2 relaxation rates
and r2 relaxivity were calculated from multiecho spin echo
(ME-SE) images scanned with 50mm FOV, plane resolu-
tion of 0.5mm, slice thickness of 2mm, TR of 2000ms,
and 32 different TEs ranging from 15 to 480ms. MRI
signal enhancement of PBNPs was measured at six different
concentrations (0.00mM, 0.125mM, 0.25mM, 0.38mM,
0.76mM, and 1.25mM). After scanning the concentration
dependent signal changes were calculated and compared to
the signal of pure water.
2.2.5. Viability Assay. Human cervical carcinoma (HeLa)
cells were chosen for cell viability assay tests. They were
seeded at a density of 104 cells/mL to each Petri dish.The cells
were exposed to saline (negative control) and three different
PBNP containing solutions (4-, 16-, and 32-fold dilutions of
PBNP) for 20min. The medium was then removed and the
cells were rinsed in Hanks’ Balanced Salt Solutions (HBSS;
Sigma-Aldrich) twice. The rinsed cells were harvested by
adding 200𝜇l of 0.1% trypsin (Sigma-Aldrich) for 3min,
then adding 800𝜇l of modified eagle medium (MEM; Sigma-
Aldrich) with 0.1% trypan blue, and counting the number of
living cells.
2.2.6. Radiolabeling with 201Tl. Thallium-201labeled PBNPs
were prepared as follows: 15 𝜇l (37MBq) [201Tl]TlCl (Covi-
dien, Netherlands) was added to 20 𝜇l PBNP in 250 𝜇l iso-
tonic 0.9% NaCl solution (Braun, Hungary) and the reaction
mixture was incubated at room temperature for 60 minutes.
The calculated specific activity of the radiolabeled product
was 62GBq/g, based on the specific activity of [201Tl]TlCl,
the size and molar weights of nonhydrated PBNPs, and the
molar amount of Fe in the reaction vial.
2.2.7. Chromatography of Radiolabeled NP Suspension.
Radiochemical purity of the labeled suspension was
determined by paper chromatography using 18 cm long
Mackerey-Nagel 813 paper strips and double distilled water
as mobile phase (𝑛 = 7). After photographic evaluation the
chromatography paper was cut into 0.5 cm pieces and the
activity of each piece was measured in a well-type NaI (Tl)
scintillation detector (NZ-310 Gamma, Budapest). Retention
factors (RF) were calculated as a ratio of the distance the
spots and the solvent front had moved from the baseline.
2.3. In Vivo Measurements
2.3.1. Animals. In vivo imaging was carried out in C57BL/6
male mice (𝑛 = 5 for SPECT/CT scans, 𝑛 = 2 for MRI
scans, Charles River, Hungary). Animals had ad libitum
access to food andwater andwere housed under temperature-
, humidity-, and light-controlled conditions. All procedures
were conducted in accordance with the ARRIVE guidelines
and the guidelines set by the EuropeanCommunities Council
Directive (86/609 EEC) and approved by the Animal Care
and Use Committee of Semmelweis University (protocol
number: XIV-I-001/29-7/2012). Mice were 10–12 weeks old
with an average body weight of 28 ± 5 g. During imaging
animals were kept under anesthesia using a mixture of 2.5%
isoflurane gas and medical oxygen. Their body temperature
was maintained at 37∘C throughout imaging.
2.3.2. SPECT/CT Imaging. Images were acquired with a
NanoSPECT/CTPLUS (Mediso Ltd., Hungary) sequential
4 Contrast Media & Molecular Imaging
animal SPECT/CT imaging system. For SPECT/CT imaging,
21.07 ± 2.38MBq of 201Tl labeled PBNP was injected in 150 𝜇l
physiological saline (Braun, Hungary) into a lateral tail vein.
During imaging animals were fixed to a MultiCellTM
Imaging Chamber (Mediso Ltd., Hungary) to avoid move-
ment and placed in the center of the FOV. Image acquisitions
startedwithCT scanning (without any contrast agent) 60min
after the intravenous injection of 201Tl-labeled PBNP. Further
SPECT/CT scans were acquired at 24, 48, and 72 hours
after injection. Both the CT and subsequent SPECT imaging
took 30min each. The reconstructed cubic voxel side size
was 150 𝜇m in a 198 × 198 × 546 voxel matrix in both the
SPECT and CT modalities. Fusion (Mediso Ltd., Hungary)
and VivoQuant (inviCRO LLC, US) image analysis software
were used to further analyze the reconstructed, reoriented,
and coregistered images by drawing appropriate volumes
of interests (VOIs) over the specified target organs. These
VOIs were delineated manually on each CT scan. Activity
concentrations (MBq/cm3) were determined for each volume
of interest and data was corrected for the scatter and isotopic
decay during the reconstruction.Organswere initially ranked
based on the visually representative uptake of activity.Then a
quantitative threshold (0.1% of injected activity) was applied
on the images. Organs with a higher uptake of 0.1% were
quantified by placing three-dimensionally corresponding
activity measuring VOIs on them. With this method the
uptake of radioactivity was selected and measured in the
following organs: liver, kidneys, salivary glands, heart, lungs,
and brain.
2.3.3. Magnetic Resonance Imaging (MRI). Images were
acquired before (prescan) and after the PBNP injection
with a nanoScan PET/MR system (Mediso, Hungary) in
a permanent magnetic field of 1 T in a 450mT/m gradient
system using a volume transmit/receive coil with a diameter
of 60mm. For imaging 1.25mM PBNP was injected in 250𝜇l
physiological saline (Braun, Hungary) into a lateral tail vein.
Two different sequences were used for imaging. T2-
weighted 2D Fast Spin Echo sequence was acquired using
the below parameters: field of view (FOV) 70mm, 0.35mm
in-plane resolution, 0.2mm slice thickness, and TR/TE
4809/70ms. T1-weighted Gradiens-echo sequence was
acquired using the below parameters: field of view (FOV)
70mm, 0.40mm in-plane resolution, 0.4mm slice thickness,
and TR/TE 3.4/25ms.
3. Results
3.1. In Vitro Measurements
3.1.1. Atomic Force Microscopy. AFM images are shown in
Figure 2. PBNPs appeared as objects with a flat rectangular
surface protruding from a rounded halo (Figure 2(a)). The
rectangular surface represents the real geometry of the parti-
cles (Figure 2(b)), while their halo is the consequence of tip
convolution, that is, the effect of imaging a rectangular prism
by a tetrahedral AFM tip. Rectangularity of the particles
(together with their halo) was found to be 0.81 ± 0.09 (mean
± SD), indicating that PBNPs indeed represent rectangular
topography. Height of the particles showed monomodal
distribution with a mean ± SD of 23.0 ± 8.3 nm (Figure 2(c)).
3.1.2. Transmission Electron Microscopy. The nonhydrated
shape and size of the NPs were also analyzed with TEM. The
shape of the nanoparticles on TEM and AFM images was
similar. PBNPs appeared as flat rectangular, dense objects in
this case as well. The mean diameter of the nanoparticles was
17.54 ± 4.56 nm (average ± SD, 𝑛 = 700) (Figure 3).
3.1.3. Zeta Potential and Light Scattering Measurement. The
mean zeta potential of PBNPs at the measured pH range did
not exceed 15mV (𝑛 = 3). At pH 7.4 the zeta potential was
−25.7 ± 1.8mV (𝑛 = 3).
The mean hydrodynamic diameter (intensity-based har-
monic mean or 𝑧-average) of citrate-coated PBNPs was 32.10
± 0.1801 (average ± SD, 𝑛 = 10), as determined by DLS. This
had only changed slightly with time.There was no significant
colloidal alteration during the 6-week duration of the study,
as the calculated 0.203 ± 0.004 polydispersity index (PDI)
shows the PBNPs did not flocculate or aggregate during this
time (not illustrated).
3.1.4.Magnetic Resonance Imaging. T1-weighted (Figure 4(a))
and T2-weighted spin echo (Figure 4(b)) images of a
phantom (containing five different concentrations (0.00mM,
0.125mM, 0.25mM, 0.38mM, 0.76mM, and 1.25mM) of
PBNP solutions and a pure solvent) were scanned to visu-
ally evaluate the signal enhancement on T1-weighted image
instead of decreased signal on T2-weighted image. Based on
the inversion prepared gradient echo scan and the multislice
multiecho scan T1 and T2 relaxation rates were calculated.
Afterward from these values, longitudinal relaxivity (𝑟1 =
0.64 ± 0.02mM−1ms−1) and transversal relaxivity values (𝑟2
= 0.96 ± 0.03mM−1ms−1) were fitted and are presented in
Table 1.
3.1.5. Viability Assay. The survival rate of HeLa cells exposed
to PBNP was above 95%. There was almost no difference
between the numbers of intact cells in case of different PBNP
concentration. For detailed information, see Table S1.
3.1.6. Stability of Radiolabeling. Using paper chromatography,
we found that both unlabeled and radiolabeled particles
have an Rf value of 0.0–0.1. Nonreacted 201Tl ions moved
together with the solvent front. Only 2% of the whole 201Tl
activity was detected at the solvent front. Therefore, the
radiochemical purity was estimated as being >98% in all
experiments (Table 2). Comparing the total added activity
of 201Tl to the solution and particle-bound 201Tl activity the
radioactive labeling yield was 99.84% (SD: 1.01%).
3.2. In Vivo Biodistribution Studies
3.2.1. SPECT/CT Imaging. Activity originating from 201Tl-
radiolabeled (doped) PBNPs was detected 2 hours after
injection in the liver (7.89 ± 2.25% ID) and in the intestines
Contrast Media & Molecular Imaging 5
200 nm
(a)
50nm
(b)
150
100
50
0
C
ou
nt
0 10 20 30 40 50
Height (nm)
(c)
Figure 2: ((a) and (b)) AFM amplitude-contrast images of PBNPs on mica surface. Contours of particles are shown by white dashed lines on
(b). (c) Height distribution of PBNPs (𝑛 = 1162).
200 nm
Figure 3: TEM image of PBNPs on carbon-coated copper grid.
(6.88 ± 1.37% ID). In later time points (24 hours, 48 hours,
and 72 hours) activity in the liver gradually decreased to
Table 1: Result of relaxivities (𝑟1 and 𝑟2), ordered to examine
concentrations of 201Tl doped PBNPs.
Relaxivity (mM−1ms−1) 𝑅 (mM−1ms−1) Error of 𝑅 (mM−1ms−1)
𝑟1 = 0.64 + / − 0.02 3089 91
𝑟2 = 0.96 + / − 0.03 2119 350
Table 2: Retention factors of 201Tl(I) ions and 201Tl doped PBNP
examined with paper chromatography.
Sample Retention factor Activity
Standard [201Tl]TlClaq 0.85 86.8%
201Tl doped PBNP 0.02 85.2%
5.92 ± 1.78%, 4.17 ± 0.43%, and 4.11 ± 0.64%, respectively.
Meanwhile, the activity in the intestines increased to 12.34 ±
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Figure 4: T1-weighted inversion prepared snapshot gradient echo
(a) and T2-weighted multiecho spin echo (b) images of a phan-
tom containing five different concentrations 0.125mM, 0.25mM,
0.38mM, 0.76mM, and 1.25mM of PBNP solutions were scanned
and signal changes compared to the bidistilled water signal.
1.67%, 19.25 ± 2.32%, and 19.48 ± 3.02%, respectively (Figures
5 and 6(a)).
In the kidneys 15.24 ± 4.06% of the injected activity was
recovered 2 hours after the administration of 201Tl doped
PBNPs, gradually decreasing to 8.45± 0.38% by 72 hours after
injection (Figures 5 and 6(b)).
In the salivary glands relatively high (0.83 ± 0.08%)
activity of 201Tl doped PBNPs was observed 2 hours after
injection. By 24 hours after injection a statistically significant
increase in salivary gland uptake was observed (1.27 ± 0.21%,
𝑝 < 0.05). By 48 and 72 hours after injection activity
measured in the salivary glands decreased to 0.78 ± 0.05%
and 0.82 ± 0.58%, respectively (Figure 6(c)).
In the heart ventricles constantly decreasing activity was
observed in every time point when compared to the initial
value of 0.59 ± 0.08% (Figures 5 and 6(c)). This is contrary to
the usually observed free 201Tl ion uptake by heart muscles
due to both the very small accumulation and the constant
decrease.
In the lungs the level of 201Tl doped PBNPs was 0.39 ±
0.29% 2 hours after injection, slightly decreasing with time to
0.29 ± 0.05% at 24 hours, 0.27 ± 0.08% at 48 hours, and 0.30
± 0.06% at 72 hours (Figure 6(d)).
In the brainnegligable PBNPuptakewas recorded 2 hours
after injection which did not increase significantly in the next
70 hours (not illustrated).
3.2.2. MRI Measurements. T2-weighted Fast Spin Echo and
T1-weighted gradient echo images were acquired to visually
evaluate the in vivo biodistribution of PBNP. No signal
changes were registered under the applied conditions com-
pared to the prescans.
4. Discussion
PB has long been used as a treatment agent of radioactive
137Cs poisoning in human medicine based on its successful
application in the accident of Goiaˆnia, Brazil [11]. It easily
adsorbs Cs+ and thus facilitating its excretion from the
human body. PB has been registered for the above indication
by Food and Drug Administration (FDA) and European
Medicines Agency (EMA) as well.
AFM is one of the foremost tools for imaging, measuring,
and manipulating subnanometer samples [12]. It measures
the shape of nonhydrated particles.The exact diameter ofNPs
was difficult to determine by AFM due to the tip convolution
which leads to artificially increased lateral dimensions on
AFM images [13]. Only the height of the particles should be
taken into account because the measured width is influenced
by tip convolution. The measured height by AFM supported
the results of TEM measurements which describe the shape
of nonhydrated particles. In both cases the particles appeared
as flat rectangular objects which represent the real geometry
of the particles. Furthermore, the size distribution of PBNP
showed monomodal distribution in cases of TEM and AFM
measurements, too.
The average diameter of our PBNPsmeasured byDLSwas
similar to the size range reported by Shokouhimehr et al. [4].
These measured hydrodynamic diameters of particles with
the small PDI values represent a monodisperse and stable
nanobased system in the investigated time frame.
According to the homogeneity and colloidal stability
results of PBNPs, the measurements of their other properties
were constant. The thermodynamic stability of PB ensured
that the synthesized PBNPs could fulfill requirements of long
stability as well.
Based on the claims found in the present study authors’
2012 US patent [10], Gallium incorporating PBNP (Ga-
PBNP) production studies were performed at the University
of Ohio [14]. The resulting structurally very similar Ga-
PBNPs to the Tl-PBNPs reported in our study have been
throughly characterized. They were also found to be cubic
shaped as shown in our results. The size differences could be
attributed to the different surface-capping agent (polyvinyl-
pyrrolidone).
Citric acid as surface-capping agent to control size and
biocompatibility and to avoid agglomeration of the syn-
thetized particles is able to chelate Ca2+ ions [15]. However,
physiological Ca2+ concentration does not affect in vivo
colloidal properties [16]. At physiological pH of 7.4, the zeta
potential of PBNPs and the steric stabilization effect of citrate
coating further enhance the colloidal stability.
MRI T1- and T2-weighted scans showed a more signifi-
cant T1 shortening effect for PBNPs than T2 shortening. Fe2+
in the PB structure is carbon-bound and has a low-spin (𝑆 =
0), while the nitrogen-bound Fe3+ has high spin (𝑆 = 5/2).
Thus, the compound is able to alter both the longitudinal and
transverse relaxation times of protons in water molecules [4].
Based on the longitudinal and transversal relaxivity results, a
local concentration in the range of 0.5mM of the 201Tl doped
PBNPs is needed to achieve properMRI signal enhancement.
In the case of in vivo MRI scans, we were not able to
register any contrast changes between the pre- and postin-
jection scans. Presumably the iron content of the injected
PBNP sample (2.5mM 250 uL PBNP) was not high enough
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Figure 5: VOI of liver, kidneys, heart, and brain (a). Biodistribution of 201Tl labeled PBNPs after 2 hours (b) and 24 hours (c) injection. The
mice were under isoflurane anesthesia during the 30 minutes long SPECT scans. The injected activity was 21.07 ± 2.38MBq.
after the intravenous administration to alter the microscopic
magnetic properties of the living system. Further chemical
improvement is needed in the future which can enhance
the iron (paramagnetic agent) content of the NP or alter
the relaxivity of our contrast material. The newly developed
iron-based contrast material should be a reliably applicable
multimodal contrast agent for in vivo biodistribution studies.
In vivo SPECT scans (based on heart and blood biodistri-
bution measurements) seem to justify that we have attained
our main goal of long-term in vivo stability of the labeled PB
particles.
No sign of 201Tl accumulation in the heart muscles points
to any significant in vivo release of free 201Tl ions from the
particles. As a “biological quality control,” no physiological
cardiomyocyte uptake of that free 201Tl (which is a potassium
ion analogue) is measured.
According to Kevin et al. the in vivo behavior of NPs
is mostly regulated by their characteristics such as size,
shape, composition, surface chemistry, and associated physi-
cal properties [17]. In accordancewith the colloidal stability of
PBNPs determined by DLS and zeta potential measurements,
they were stable in vivo and they did not aggregate in a
biologically relevant manner.
The reported citrate-coated PBNPs accumulate in the
liver followed by biliary excretion into the intestines. The
measured activity in the liver gradually decreased, while the
activity in the intestines increased during the 72-hour time
period. Uptake mechanisms by Kuppfer cells favor larger,
negatively charged particles and are responsible for the reten-
tion of most NPs in the liver. Other cell types (liver sinusoidal
endothelial cells (LSEC), hepatic stellate cells (HSC), hep-
atocytes, cholangiocytes, and resident immune cells) also
interact with NPs. Uptake by hepatocytes favors smaller
and more positively charged particles and leads to their
hepatobiliary clearance [18]. Based on the available literature,
the size of our PBNPs suggests they were able to extravasate
into the spaces of Disse where they were most likely taken up
directly by hepatocytes. Kupffer cells and LSECs uptake could
have also taken place based on the measured zeta potential.
The assumption of Disse-space extravasation and hepatocyte
uptake could be further investigated with ultrastructural
methods as it represents a targeting opportunity.
Histological examination of previous studies about the
biodistribution of NPs provides imporant insight into the
routes of accumulation of PBNPs inside the kidneys [19–
21]. Based on these experiments, filtration of PBNPs is not
possible due to their negative charge and large size; larger
PBNPs deposit in the mesangium while smaller NPs remain
inside the peritubular vessels.
Kaiser et al. published that salivary glands took up
some hydrophilic and negatively charged, cubic shaped NPs
already one hour after the i.v. administration [22]. With
regard to early tissue distribution pattern of NPs (in our
study 2 hours after injection), our results were similar to
those of other research groups [17]. The accumulation of our
201Tl doped PBNPs in the salivary glands was continuous
in the first 24 hours due to the negative surface charge of
PBNPs (negative zeta potential) and the abundance of sodium
hydrogen carbonate (NaHCO
3
) in the salivary glands which
are essencial for entrapping the injected PBNPs. 48 hours
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Figure 6: The biodistribution of 201Tl doped PBNPs in (a) intestines (square) and liver (diamond), (b) kidneys (square); (c) salivary glands
(square) and heart (diamond); and (d) lungs (diamond) in 2, 24, 48, and 72 hours after injection. Brain uptake constantly remained under
the threshold level. The mice were under isoflurane anesthesia during the 30 minutes long SPECT scans. The injected activity was 21.07 ±
2.38MBq.
after injection the activity detected in the salivary glands
decreased most probably due to the excretion of PBNPs into
the saliva. Activity levels in the salivary glands decreased and
in parallel activity recovered from the intestines continued to
increase due to continuous hepatic excretion.
The heart, skeletal muscles, and lungs are not supposed
to accumulate PBNPs. The very small radioactivity detected
in these organs could be the result of a minuscule proportion
of 201Tl ions probably released by PBNPs in the bloodstream,
where just like in the liver and in the intestines the activity is
decreasing.
Because of the radioactive metal binding capability of
PBNPs (e.g., 201Tl-labeled PBNP), it could be a useful SPECT
tracer in preclinical research (in biliary obstructive diseases
(e.g., hepatocarcinoma, pancreatic tumors) due to the high
and intensive liver uptake and biliary excretion [18]) and
could have the potential for translation into clinical practice
too. 201Tl could be substituted with other radiometals that
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similarly could be doping the PB structure to 201Tl, for
example, the beta emitters 64Cu, 90Sr, 90Y, and 161Tb and the
alpha emitters 149Tb and 213Bi.
Altogether further development of our NP platform for
dual diagnostic and therapeutic functions (theranostics) is
of great interest [1]; appropriately modified PBNPs could
fulfill the above-mentioned criteria and be useful for the
diagnosis and therapy of various diseases including the local
radiotherapy of cancer.
5. Conclusions
In this study, we successfully synthesized, characterized, and
demonstrated the biodistribution of citrate-coated Prussian
blue nanoparticles labeled using 201Tl isotope. The results
show a chemically stable and biocompatible 201Tl-labeled
nanoparticulate SPECT tracer. Important hepatic and sali-
vary glands uptake was seen to be of particular interest upon
evaluation of the particle biodistribution. These PB-based
particles could be applied as a drug delivery platform or a
contrast agent in preclinical research. They could further be
tailored towards clinical application, too.
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